Decode News AI
简体繁體

Alpha Tau Radiation Trial Reports All 8 Brain Cancer Patients Alive

2026-11-16 10:41 EST · AI-compiled · 243 words · about 1 min · Views …
Photo: AI-generated illustration

JERUSALEM - Alpha Tau Medical announced on Nov. 15, 2026, that all eight recurrent glioblastoma patients treated in its U.S. REGAIN trial remained alive as of Nov. 11, with all six evaluable patients achieving objective tumor responses.

Minimally Invasive Implants Yield Five Complete Responses

Clinicians at The Ohio State University Comprehensive Cancer Center delivered Alpha DaRT radium-224 sources into brain tumors through minimally invasive burr-hole access without open craniotomy. Among the six patients who reached MRI assessment, five achieved complete responses (83.3%) and one achieved a partial response (16.7%) with a 58% reduction in tumor measurements. Median follow-up for the six evaluable patients reached 6.9 months, and median overall survival had not been reached.

Investigators Point to Survival Signals in Aggressive Cancer

Joshua Palmer said.

Asymptomatic Necrosis and Small Sample Warrant Longer Follow-Up

Alpha Tau reported 100% procedural feasibility and no unanticipated serious adverse events across all eight patients, though asymptomatic or suspected radiation necrosis appeared on scans in four of six evaluable patients. Two patients require additional imaging to distinguish necrosis from tumor progression, and Alpha DaRT remains investigational without FDA approval for glioblastoma.

Sources

Found a factual error or typo? Tell us

Follow Decode News AI on Telegram

Live updates: every new story is pushed the moment it publishes — dozens a day, no digest delay.

@decodenewsai · Subscribe now

Free · unsubscribe anytime

Comments